Patents Assigned to Pharmacia Corporation
  • Method for the treatment or prevention of respiratory disorders with a cyclooxygenase-2 inhibitor in combination with a muscarinic receptor antagonist and compositions therewith
    Publication number: 20050107349
    Abstract: The present invention relates to a novel method of preventing and/or treating respiratory disorders and respiratory disorder-related complications in a subject by administering to the subject at least one Cox-2 inhibitor in combination with one or more muscarinic receptor antagonists. Compositions, pharmaceutical compositions and kits are also described.
    Type: Application
    Filed: April 28, 2004
    Publication date: May 19, 2005
    Applicant: Pharmacia Corporation
    Inventor: Karen Seibert
  • Method and compositions for the treatment and prevention of pain and inflammation
    Publication number: 20050101563
    Abstract: A method of preventing or treating pain or inflammation in a subject is provided by administering to the subject a Cox-2 inhibitor and a polyunsaturated fatty acid, or a prodrug thereof, wherein the amount of a Cox-2 inhibitor and polyunsaturated fatty acid or a pharmaceutically acceptable salt or prodrug thereof together constitute a pain or inflammation suppressing treatment or prevention effective amount. Glucosamine and/or chondroitin can optionally be present. Therapeutic compositions that contain the combination of Cox-2 inhibitor and polyunsaturated fatty acid and, optionally, the glucosamine and/or chondroitin, are disclosed, as are pharmaceutical compositions.
    Type: Application
    Filed: February 19, 2004
    Publication date: May 12, 2005
    Applicant: Pharmacia Corporation
    Inventors: Steven Pulaski, Susan Kundel
  • Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors
    Publication number: 20050101623
    Abstract: The present invention provides novel bridged beta-carboline compounds that are capable of inhibiting mitogen activated protein kinase-activated protein kinase-2 and analogues thereof and pharmaceutical compositions and kits that include these compounds.
    Type: Application
    Filed: July 20, 2004
    Publication date: May 12, 2005
    Applicant: Pharmacia Corporation
    Inventors: Marvin Meyers, David Anderson, Shridhar Hegde, John Trujillo, David Reitz, Matthew Mahoney, William Vernier, Ingrid Buchler, Kun Wu
  • Compositions of a chromene cyclooxygenase-2 selective inhibitor and a cholinergic agent for the treatment of reduced blood flow or trauma to the central nervous system
    Publication number: 20050101629
    Abstract: The present invention provides compositions and methods for the treatment of central nervous system damage in a subject. More particularly, the invention provides a combination therapy for the treatment of a central nervous system ischemic condition or a central nervous system traumatic injury comprising the administration to a subject of a cholinergic agent in combination with a chromene cyclooxygenase-2 selective inhibitor.
    Type: Application
    Filed: May 13, 2004
    Publication date: May 12, 2005
    Applicant: Pharmacia Corporation
    Inventors: Diane Stephenson, Duncan Taylor, Stephen Arneric
  • Aromatic sulfone hydroxamic acids and their use as protease inhibitors
    Patent number: 6890928
    Abstract: This invention is directed to aromatic sulfone hydroxamic acids (including hydroxamates) and salts thereof that, inter alia, inhibit matrix metalloproteinase (also known as “matrix metalloprotease” or “MMP”) activity and/or aggrecanase activity. This invention also is directed to a prevention or treatment method that comprises administering such a compound or salt in an MMP-inhibiting and/or aggrecanase-inhibiting effective amount to an animal, particularly a mammal having (or disposed to having) a pathological condition associated with MMP and/or aggrecanase activity.
    Type: Grant
    Filed: September 5, 2003
    Date of Patent: May 10, 2005
    Assignee: Pharmacia Corporation
    Inventors: John N. Freskos, Yvette M. Fobian, Thomas E. Barta, Daniel P. Becker, Louis J. Bedell, Terri L. Boehm, Jeffrey N. Carroll, Gary A. DeCrescenzo, Susan L. Hockerman, Darren J. Kassab, Steve A. Kolodziej, Joseph McDonald, Deborah A. Mischke, Monica B. Norton, Joseph G. Rico, John J. Talley, Clara I. Villamil, Lijuan Jane Wang
  • Aromatic sulfone hydroxamic acid metalloprotease inhibitor
    Patent number: 6890937
    Abstract: A treatment process is disclosed that comprises administering an effective amount of an aromatic sulfone hydroxamic acid that exhibits excellent inhibitory activity of one or more matrix metalloprotease (MMP) enzymes, such as MMP-2, MMP-9, and MMP-13, while exhibiting substantially less inhibition at least of MMP-1 to a host having a condition associated with pathological matrix metalloprotease activity. The administered enzyme inhibitor corresponds in structure to formula (I), below, or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are both hydrido or R1 and R2 together with the atoms to which they are bonded form a 5- to 8-membered ring containing one, two, or three heteroatoms in the ring that are oxygen, sulfur, or nitrogen. R3 in formula (I) is an optionally substituted aryl or optionally substituted heteroaryl radical.
    Type: Grant
    Filed: January 7, 2003
    Date of Patent: May 10, 2005
    Assignee: Pharmacia Corporation
    Inventors: Thomas E. Barta, Daniel P. Becker, Louis J. Bedell, Terri L. Boehm, Jeffery N. Carroll, Gary A. DeCrezcenzo, Theresa R. Fletcher, John N. Freskos, Daniel P. Getman, Gunnar J. Hanson, Susan L. Hockerman, Carol P. Howard, Stephen A. Kolodziej, Madeleine H. Li, Joseph J. McDonald, Deborah A. Mischke, Patrick B. Mullins, Joseph G. Rico, Nathan W. Stehle, Clara I. Villamil
  • Method for the preparation of tetrahydrobenzothiepines
    Publication number: 20050090543
    Abstract: Among its several embodiments, the present invention provides an improved process for the preparation of tetrahydrobenzothiepine-1,1-dioxide compounds; the provision of a process for preparing a diastereomeric mixture of tetrahydrobenzothiepine-1,1-dioxide compounds from a single diastereomer of such compounds; the provision of a process for the preparation of 3-bromo-2-substituted propionaldehyde compounds; and the provision of a process for the preparation of 3-thio-2-substituted propionaldehyde compounds.
    Type: Application
    Filed: May 19, 2004
    Publication date: April 28, 2005
    Applicant: Pharmacia Corporation
    Inventors: Kevin Babiak, Andrew Carpenter, Shine Chou, Pierre-Jean Colson, Farid Payman, Robert Hett, Christian Huber, Kevin Koeller, Jon Lawson, James Li, Eduardo Mar, Lawrence Miller, Vladislav Orlovski, James Peterson, Mark Pozzo, Claire Przybyla, Samuel Tremont, Jay Trivedi, Grace Wagner, Gerald Weisenburger, Benxin Zhi
  • Steroid spirolactonization
    Publication number: 20050090663
    Abstract: A steroid comprising a 17-spirolactone or corresponding open lactone structure is obtained by carbonylation of a 17-alkenyl or 17-alkynyl substrate. A 17-alkenyl intermediate may be prepared by semi-hydrogenation of a 17-alkynyl group. Multiple reaction schemes are disclosed for preparation of a 3-keto-9,11-epoxy-17-spirolactone steroid such as eplerenone. Novel intermediates are also disclosed, as well as steps for forming such novel intermediates, or converting them to further intermediates or products, by semi-hydrogenation, carbonylation, 6,7-dehydrogenation, furylation or other transformations or combinations thereof.
    Type: Application
    Filed: March 22, 2004
    Publication date: April 28, 2005
    Applicant: Pharmacia Corporation
    Inventors: Thaddeus Franczyk, Grace Wagner, Bruce Pearlman, Amphlett Padilla, Jeffrey Havens, Sonja Mackey, Haifeng Wu
  • Process for decreasing aggregate levels of pegylated protein
    Publication number: 20050085631
    Abstract: The present invention is directed generally to recombinant methods for making a desired pegylated protein and pooling of same. These method(s) yield a polypeptide product containing reduced levels of aggregate thereof pooled to provide the desired pegylated isoforms thereof.
    Type: Application
    Filed: September 22, 2003
    Publication date: April 21, 2005
    Applicant: Pharmacia Corporation
    Inventors: Denis Boyle, John Buckley, Gary Johnson, David Steinmeyer, Michele Toal, Serdar Aykent, Anurag Rathore
  • Compositions of a cyclooxygenase-2 selective inhibitor and an angiotensin II receptor antagonist for the treatment of central nervous system damage
    Publication number: 20050080083
    Abstract: The present invention provides compositions and methods for the treatment of central nervous system damage in a subject. More particularly, the invention provides a combination therapy for the treatment of a central nervous system ischemic condition or a central nervous system traumatic injury comprising the administration to a subject of an angiotensin II receptor antagonist in combination with a cyclooxygenase-2 selective inhibitor.
    Type: Application
    Filed: July 8, 2004
    Publication date: April 14, 2005
    Applicant: Pharmacia Corporation
    Inventors: Diane Stephenson, Duncan Taylor
  • Compositions of a cyclooxygenase-2 selective inhibitor and an IKK inhibitor for the treatment of ischemic mediated central nervous system disorders or injury
    Publication number: 20050075341
    Abstract: The present invention provides compositions and methods for the treatment of ischemic-mediated central nervous system disorders or injuries. More particularly, the invention provides a combination therapy for the treatment of a central nervous system ischemic-mediated disorder or injury comprising the administration to a subject of a cyclooxygenase-2 selective inhibitor and an IKK inhibitor.
    Type: Application
    Filed: July 15, 2004
    Publication date: April 7, 2005
    Applicant: Pharmacia Corporation
    Inventor: Diane Stephenson
  • Polycyclic aryl and heteroaryl substituted 4-pyrones useful for selective inhibition of the coagulation cascade
    Patent number: 6875791
    Abstract: The invention relates to polycyclic aryl and heteroaryl substituted 4-pyrone compounds useful as inhibitors of serine proteases of the coagulation cascade and compounds, compositions and methods for anticoagulant therapy for the treatment and prevention of a variety of thrombotic conditions including coronary artery and cerebrovascular diseases.
    Type: Grant
    Filed: April 4, 2001
    Date of Patent: April 5, 2005
    Assignee: Pharmacia Corporation
    Inventors: Michael S. South, Chun C. Ma, Kevin J. Koeller, Hayat K. Rahman, William L. Neumann
  • Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
    Patent number: 6875785
    Abstract: This invention is in the field of antiinflammatory pharmaceutical agents and specifically relates to compounds, compositions and methods for treating disorders mediated by cyclooxygenase-2 or 5-lipoxygenase, such as inflammation.
    Type: Grant
    Filed: September 25, 2002
    Date of Patent: April 5, 2005
    Assignee: Pharmacia Corporation
    Inventors: John J. Talley, James A. Sikorski, Matthew J. Graneto, Jeffery S. Carter, Bryan H. Norman, Balekudru Devadas, Hwang-Fun Lu
  • Cyclic sulfone containing retroviral protease inhibitors
    Patent number: 6875790
    Abstract: The present invention relates to cyclic sulfone moiety-containing hydroxyethylamine protease inhibitor compounds and pharmaceutical or method of use therefor, particularly as an inhibitor of HIV protease.
    Type: Grant
    Filed: February 20, 2003
    Date of Patent: April 5, 2005
    Assignees: G. D. Searle & Co., Pharmacia Corporation (Monsanto Corporation)
    Inventors: Deborah E. Bertenshaw, Daniel Getman, Robert M. Heintz, John J. Talley, Kathryn L. Reed, Robert Alan Chrusciel, Michael Clare
  • Solid-state forms of N-(2-hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidinyl)-3-(4-chlorophenyl) pyrazole
    Patent number: 6872725
    Abstract: Crystalline forms of the p38 kinase inhibitor N-(2-hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidinyl)-3-(4-chlorophenyl)pyrazole are provided. These crystalline forms include (a) a first anhydrous crystalline form possessing improved physical stability relative to other solid-state forms of the compound; (b) a second anhydrous crystalline form possessing unique properties relative to other solid-state forms of the compound; (c) a third anhydrous crystalline form possessing unique properties relative to other solid-state forms of the compound; and (d) solvated crystalline forms, hydrated crystalline forms, and crystalline salt forms of the compound that are useful, for example, as intermediate solid-state forms in the preparation of other crystalline forms of the compound.
    Type: Grant
    Filed: September 25, 2002
    Date of Patent: March 29, 2005
    Assignee: Pharmacia Corporation
    Inventors: Kimberley C. Allen, Jerry D. Clark, Thomas P. Fraher, Jason A. Hanko, Kimberly L. Kolbert, Clay R. Little, Michael K. Mao, Patricia S. Miyake, Jodi L. Moe, Partha S. Mudipalli, Tobin C. Schilke, Christine B. Seymour, Ahmad Y. Sheikh, Gopichand Yalamanchili
  • Method of changing conformation of a matrix metalloproteinase
    Patent number: 6869951
    Abstract: The present invention provides a matrix metalloproteinase inhibiting compound having structure (VIII) or a salt, an enantiomer, a diastereomer, a racemate, or a tautomer thereof. In other embodiments, the present invention provides a method of changing the conformation of a matrix metalloproteinase, a method of inhibiting a matrix metal metalloproteinase, and a method of treating osteoarthritis.
    Type: Grant
    Filed: July 12, 2000
    Date of Patent: March 22, 2005
    Assignee: Pharmacia Corporation
    Inventors: William C. Stallings, Huey S. Shieh, Susan C. Howard, Gary A. DeCrescenzo, Joseph J. McDonald
  • Substitituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade
    Patent number: 6870056
    Abstract: The invention relates to substituted polycyclic aryl and heteroaryl pyridone compounds useful inhibitors of serine proteases of the coagulation cascade and compounds, compositions and methods for anticoagulant therapy for the treatment and prevention of a variety of thrombotic conditions including coronary artery and cerebrovascular diseases.
    Type: Grant
    Filed: November 20, 2000
    Date of Patent: March 22, 2005
    Assignee: Pharmacia Corporation
    Inventors: Michael S. South, Qingieng Zeng, Melvin L. Rueppel, Ashton T. Hamme, II
  • Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade
    Patent number: 6867217
    Abstract: The invention relates to substituted polycyclic aryl and heteroaryl pyridone compounds useful as inhibitors of serine proteases of the coagulation cascade and compounds, compositions and methods for anticoagulant therapy for the treatment and prevention of a variety of thrombotic conditions including coronary artery and cerebrovascular diseases.
    Type: Grant
    Filed: May 18, 2000
    Date of Patent: March 15, 2005
    Assignee: Pharmacia Corporation
    Inventors: Michael S. South, Qingping Zeng, Ashton T. Hamme, II, Melvin L. Rueppel
  • Stable amorphous celecoxib composite and process therefor
    Patent number: 6864373
    Abstract: A process is provided for preparing a celecoxib-crystallization inhibitor composite wherein at least a detectable amount of celecoxib is in amorphous form. Also provided are compositions prepared according to such a process. Also provided is a method of treating a medical condition or disorder in a subject where treatment with a cyclooxygenase-2 inhibitor is indicated, comprising administering, for example orally, a composition of the invention in a therapeutically effective amount.
    Type: Grant
    Filed: May 8, 2003
    Date of Patent: March 8, 2005
    Assignee: Pharmacia Corporation
    Inventors: Hong Zhuang, Ping Gao
  • Alkyl/aryl hydroxy or keto thiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake
    Patent number: 6852753
    Abstract: Thiepine apical sodium co-dependent bile acid transport (ASBT) inhibitors are disclosed together with methods of making the same, methods of using the same to treat hyperlipidemic conditions as well as pharmaceutical compositions containing the same compounds.
    Type: Grant
    Filed: January 15, 2003
    Date of Patent: February 8, 2005
    Assignee: Pharmacia Corporation
    Inventors: Kevin J. Koeller, Samuel J. Tremont